114 related articles for article (PubMed ID: 9867528)
21. Enoxaparin in elective percutaneous coronary intervention.
Bhala N
N Engl J Med; 2006 Dec; 355(26):2788; author reply 2790-1. PubMed ID: 17192548
[No Abstract] [Full Text] [Related]
22. [Summary and perspectives. Rivaroxaban].
Albaladejo P
Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S28-31. PubMed ID: 19185785
[TBL] [Abstract][Full Text] [Related]
23. Enoxaparin in elective percutaneous coronary intervention.
Schuler J; Altenberger J; Heigert M
N Engl J Med; 2006 Dec; 355(26):2789-90; author reply 2790-1. PubMed ID: 17193723
[No Abstract] [Full Text] [Related]
24. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Levine M; Gent M; Hirsh J; Leclerc J; Anderson D; Weitz J; Ginsberg J; Turpie AG; Demers C; Kovacs M
N Engl J Med; 1996 Mar; 334(11):677-81. PubMed ID: 8594425
[TBL] [Abstract][Full Text] [Related]
25. [The role of heparin in prevention of deep veins thrombosis and pulmonary artery thromboembolism in therapeutic regime patients].
Panchenko EP
Klin Med (Mosk); 2001; 79(3):59-62. PubMed ID: 11490422
[TBL] [Abstract][Full Text] [Related]
26. Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population.
Reeves D; Liu CY
J Oncol Pharm Pract; 2010 Mar; 16(1):27-31. PubMed ID: 19401307
[TBL] [Abstract][Full Text] [Related]
27. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
Decousus H; Leizorovicz A; Parent F; Page Y; Tardy B; Girard P; Laporte S; Faivre R; Charbonnier B; Barral FG; Huet Y; Simonneau G
N Engl J Med; 1998 Feb; 338(7):409-15. PubMed ID: 9459643
[TBL] [Abstract][Full Text] [Related]
28. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Bergqvist D; Agnelli G; Cohen AT; Eldor A; Nilsson PE; Le Moigne-Amrani A; Dietrich-Neto F;
N Engl J Med; 2002 Mar; 346(13):975-80. PubMed ID: 11919306
[TBL] [Abstract][Full Text] [Related]
29. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.
Eriksson BI; Bauer KA; Lassen MR; Turpie AG;
N Engl J Med; 2001 Nov; 345(18):1298-304. PubMed ID: 11794148
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for venous thromboembolism.
Lawrence YR
Arch Intern Med; 2004 Nov; 164(21):2386. PubMed ID: 15557421
[No Abstract] [Full Text] [Related]
31. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group.
Colwell CW; Spiro TE; Trowbridge AA; Stephens JW; Gardiner GA; Ritter MA
Clin Orthop Relat Res; 1995 Dec; (321):19-27. PubMed ID: 7497668
[TBL] [Abstract][Full Text] [Related]
32. Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients.
Francis CW
N Engl J Med; 2007 Apr; 356(14):1438-44. PubMed ID: 17409325
[No Abstract] [Full Text] [Related]
33. Enoxaparin for the prevention of VT in acutely ill patients.
Tseng CW; Huntington J
J Fam Pract; 1999 Dec; 48(12):940-1. PubMed ID: 10628571
[No Abstract] [Full Text] [Related]
34. Enoxaparin for the prevention of venous thromboembolism.
Axon RN; Cawley PJ
Hosp Pract (1995); 2010 Feb; 38(1):112-4. PubMed ID: 20469632
[No Abstract] [Full Text] [Related]
35. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.
Bauer KA; Eriksson BI; Lassen MR; Turpie AG;
N Engl J Med; 2001 Nov; 345(18):1305-10. PubMed ID: 11794149
[TBL] [Abstract][Full Text] [Related]
36. [Venous thromboembolism prophylaxis with low molecular weight heparins in polytraumatized patients in intensive care unit (extended serie)].
Kurtoğlu M; Büyükkurt CD; Kurtoğlu M; Dural CA; Güloğlu R; Akar U
Ulus Travma Acil Cerrahi Derg; 2003 Jan; 9(1):37-44. PubMed ID: 12587053
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism.
Deitelzweig SB; Becker R; Lin J; Benner J
Thromb Haemost; 2008 Nov; 100(5):810-20. PubMed ID: 18989525
[TBL] [Abstract][Full Text] [Related]
38. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
[TBL] [Abstract][Full Text] [Related]
39. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial.
Veiga F; Escribá A; Maluenda MP; López Rubio M; Margalet I; Lezana A; Gallego J; Ribera JM
Thromb Haemost; 2000 Oct; 84(4):559-64. PubMed ID: 11057850
[TBL] [Abstract][Full Text] [Related]
40. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group.
Bergmann JF; Neuhart E
Thromb Haemost; 1996 Oct; 76(4):529-34. PubMed ID: 8902991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
